Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (NC-005)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02193776
Recruitment Status : Completed
First Posted : July 18, 2014
Results First Posted : July 26, 2019
Last Update Posted : July 26, 2019
Sponsor:
Information provided by (Responsible Party):
Global Alliance for TB Drug Development

Tracking Information
First Submitted Date  ICMJE July 16, 2014
First Posted Date  ICMJE July 18, 2014
Results First Submitted Date  ICMJE February 22, 2019
Results First Posted Date  ICMJE July 26, 2019
Last Update Posted Date July 26, 2019
Actual Study Start Date  ICMJE October 23, 2014
Actual Primary Completion Date February 8, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 28, 2019)
Rate of Change in Time to Sputum Culture Positivity (TTP) Over 8 Weeks in the Mycobacterial Growth Indicator Tube (MGIT) System [ Time Frame: Day 0 to Day 56 (8 weeks) ]
The bactericidal activity (BA) was determined by the rate of change in TTP collected from overnight sputum samples over 8 weeks of treatment in the liquid culture media MGIT system, represented by the model-fitted log(TTP) results as calculated by the regression of the observed log(TTP) results over time. The bactericidal activity of log(TTP) over Day 0 to Day 56 (BATTP[0-56]) was presented and expressed as the daily percentage change in TTP from Day 0 to Day 56. The mean BATTP (0-56) was calculated from Bayesian non-linear mixed effects regression models fitted to log(TTP) collected from sputum samples (observed from Day 0 to Day 56).
Original Primary Outcome Measures  ICMJE
 (submitted: July 16, 2014)
The Bactericidal Activity as determined by the rate of change in time to sputum culture positivity, Days 0 - 56. [ Time Frame: 8 weeks. Prior to the initial dose on days -2 and -1, and following the initial dose, on days 1,3,7,14,21,28,35,42,49, and 56. ]
The Bactericidal Activity (BA,TTP[0-56]) as determined by the rate of change in time to sputum culture positivity (TTP) over 8 weeks of treatment in the Mycobacterial Growth Indicator Tube system, represented by the model-fitted log(TTP) results as calculated by the regression of the observed log(TTP) results over time.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 28, 2019)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: First study drug administration (Day 1) up to and including the Day 70 follow-up visit (or up to and including 14 days after last study drug administration for participants not having the Day 70 follow-up visit) (70 days) ]
A TEAE was defined as any AE which started or worsened on or after first study drug administration up to and including the Day 70 follow-up visit (or up to and including 14 days after last study drug administration for participants not having Day 70 follow-up visit). Drug-related TEAEs were defined as TEAEs for which relationship to study drug was indicated as 'possible', 'probable', 'certain' or missing. TEAEs leading to death were defined as TEAEs resulted 'fatal' outcome. Serious TEAEs were defined as TEAEs for which serious was indicated as 'yes'. TEAEs leading to discontinuation of study drug were defined as TEAEs for which action taken with study drug was indicated as 'study drug stopped'. TEAEs leading to early withdrawal from study were defined as TEAEs resulted study discontinuation. Grade III and IV TEAEs were defined as TEAEs for which severity (DMID grade) was indicated as 'Grade 3 (severe)' and 'Grade 4 (potentially life-threatening)' or missing, respectively.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 16, 2014)
  • The Bactericidal Activity as determined by the rate of change in time to sputum culture positivity, Days 0 - 2. [ Time Frame: 2 days. Prior to the initial dose on days -2 and -1, and following the initial dose, on days 1 and 3. ]
    The Bactericidal Activity (BA,TTP[0-2]) as determined by the rate of change in time to sputum culture positivity (TTP) over Days 0 to 2 represented by the model-fitted log(TTP) as calculated by the regression of the observed log(TTP) counts over time.
  • The Bactericidal Activity as determined by the rate of change in time to sputum culture positivity, Days 14 - 56. [ Time Frame: 42 days. Days 14,21,28,35,42,49, and 56 after the initial dose. ]
    The Bactericidal Activity (BA,TTP[14-56]) as determined by the rate of change in time to sputum culture positivity (TTP) over Days 14 to 56 of treatment, represented by the model-fitted log(TTP) as calculated by the regression of the observed log(TTP) counts over time.
  • The Bactericidal Activity as determined by the rate of change in colony forming units, Days 0 - 56. [ Time Frame: 56 days. Prior to the initial dose on days -1 and -2, and post-dose on days 1,3,7,14,21,28,35,42,49, and 56. ]
    The Bactericidal Activity (BA,CFU[0-56]) as determined by the rate of change in colony forming units (CFU) over 8 weeks of treatment represented by the model-fitted log(CFU) results as calculated by the regression of the observed log(CFU) results over time.
  • The Bactericidal Activity as determined by the rate of change in colony forming units, Days 0 - 2. [ Time Frame: 2 days. Prior to the initial dose on days -1 and -2, and following the initial dose, on days 1 and 3. ]
    The Bactericidal Activity (BACFU[0-2]) as determined by the rate of change in colony forming units (CFU) over 8 weeks of treatment represented by the model-fitted log(CFU) results as calculated by the regression of the observed log(CFU) results over time.
  • The Bactericidal Activity as determined by the rate of change in colony forming units, Days 14 - 56. [ Time Frame: 42 days. Days 14,21,28,35,42,49, and 56 after the initial dose. ]
    The Bactericidal Activity (BACFU[14-56]) as determined by the rate of change in colony forming units (CFU) over 8 weeks of treatment represented by the model-fitted log(CFU) results as calculated by the regression of the observed log(CFU) results over time.
  • Time to sputum culture conversion using data from solid media, Days 0 - 56. [ Time Frame: 56 days. Prior to the initial dose on days -1 and -2, and post-dose on days 1,3,7,14,21,28,35,42,49, and 56. ]
    Time to sputum culture conversion using data from weekly solid media (Löwenstein-Jensen medium) cultures through 8 weeks of treatment.
  • Time to sputum culture conversion using data from liquid media, Days 0 - 56. [ Time Frame: 56 days. Prior to the initial dose on days -1 and -2, and post-dose on days 1,3,7,14,21,28,35,42,49, and 56. ]
    Time to sputum culture conversion using data from weekly cultures through 8 weeks of treatment using liquid (Mycobacterial Growth Indicator Tube) media.
  • Pharmacokinetic analysis of Ctrough of Investigational Medicinal Products, Days 0 - 70. [ Time Frame: 70 days. Samples will be collected pre-dose on Days 1, 4, 8, 15, 22, 29, 36, 43, 50 and during the site visit on Days 57 and 70. ]
    The lowest (trough) concentration before the next dose is administered of bedaquiline, bedaquiline metabolite M2, Pa-824, and pyrazinimide [DS-TB subjects in arms J(loading dose/t.i.w.)PaZ and J(200mg)PaZ) and MDR-TB arm J(200mg)MPaZ]. The trough concentration will also be measured for moxifloxacin in the MDR-TB J(200mg)MPaZ arm and pyrazinimide in the DS-TB HRZE arm.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
Official Title  ICMJE A Phase 2 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide During 8 Weeks of Treatment in Adult Subjects With Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear-Positive Pulmonary Tuberculosis.
Brief Summary The purpose of this study is to determine the mycobactericidal activity of combinations of bedaquiline (J), moxifloxacin (M), PA-824 (Pa) and pyrazinamide (Z) regimens during 8 weeks of treatment.
Detailed Description

The trial design is a phase 2, multi-center, open-label, partially randomized clinical trial in four parallel treatment groups. Subjects with drug-sensitive tuberculosis (DS-TB) will be randomized to receive either J(loading dose/three times a week)PaZ; or J(200mg)PaZ; or HRZE. Subjects with multi drug-resistant tuberculosis will receive J(200mg)MPaZ. The HRZE treatment arm is included as a control for the drug-sensitive treatments and as a control for the quantitative laboratory mycobacteriology testing.

A total of approximately 240 male and female, newly diagnosed subjects with drug-sensitive or multi drug-resistant, smear positive pulmonary tuberculosis aged 18 to 75 years (inclusive) will be included in the study. A total of 180 subjects with drug-sensitive tuberculosis (60 per treatment arm) will be randomized. Up to 60 subjects with multi-drug resistant tuberculosis will be assigned.

All subjects will have up to a maximum of 9 days screening, receive 8 weeks of treatment, and have follow-up visits at 2 and 12 weeks after study treatment completion or last dose of investigational medicinal product in the case of early withdrawal. Subjects who withdraw from the study after receiving < 14 days of investigational medicinal product, will only attend a follow-up visit at 2 weeks after last dose of investigational medicinal product.

Upon treatment completion, the subjects with drug-sensitive tuberculosis will be provided with sufficient doses of standard of care tuberculosis treatment, as appropriate, to cover the time period from attending their last visit at the study clinic until their scheduled visit at the TB clinic. All subjects with drug sensitive and multi-drug resistant tuberculosis will be referred to the local community tuberculosis clinics for standard anti-tuberculosis chemotherapy according to National Tuberculosis Guidelines.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Tuberculosis
Intervention  ICMJE
  • Drug: PA-824
    oral
  • Drug: bedaquiline
    oral
    Other Names:
    • TMC207
    • Sirturo
  • Drug: moxifloxacin
    oral
    Other Names:
    • BAY 12-8039
    • Avelox
    • Avalon
    • Avelon
  • Drug: pyrazinamide
    oral
  • Drug: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
    oral
Study Arms  ICMJE
  • Experimental: DS-TB: J(loading dose/t.i.w.)PaZ
    Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
    Interventions:
    • Drug: PA-824
    • Drug: bedaquiline
    • Drug: pyrazinamide
  • Experimental: DS-TB: J(200mg)PaZ
    Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
    Interventions:
    • Drug: PA-824
    • Drug: bedaquiline
    • Drug: pyrazinamide
  • Experimental: MDR-TB: J(200mg)MPaZ
    Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
    Interventions:
    • Drug: PA-824
    • Drug: bedaquiline
    • Drug: moxifloxacin
    • Drug: pyrazinamide
  • Active Comparator: DS-TB: HRZE
    Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
    Intervention: Drug: isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet
Publications * Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 16, 2014)
240
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE February 7, 2018
Actual Primary Completion Date February 8, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Provide written, informed consent prior to all trial-related procedures. Male or female, aged between 18 and 75 years inclusive.
  2. Body weight (in light clothing and with no shoes) between 35 and 100 kg, inclusive.
  3. Tested at the trial appointed laboratory: M. Tb positive on molecular test (e.g. GeneXpert or Hain) and sputum smear-positive pulmonary TB on direct microscopy for acid-fast bacilli (at least 1+ on the IUATLD/WHO scale.

    • For DS-TB treatment arms (defined as sensitive to rifampicin based on molecular sensitivity testing), Subjects should be:

      1. either newly diagnosed or untreated for at least 3 years after cure from a previous episode (Subject can give a history of cure and previous treatment); AND
      2. Previous TB treatment must be discontinued as per exclusion criteria 16.
    • For MDR-TB treatment arm (defined as resistant to rifampicin based on molecular sensitivity testing), Subjects should be:

      1. sensitive to moxifloxacin by molecular sensitivity testing; AND
      2. either newly diagnosed or could have previously been treated for DS-TB and/or MDR-TB (< 7 days of treatment). Previous MDR-TB treatment must be discontinued as per exclusion criteria 17.
  4. A chest X-ray picture which in the opinion of the Investigator is compatible with TB.
  5. Ability to produce an adequate volume of sputum as estimated from a screening Coached Spot Sputum Sample assessment (estimated 10 ml or more overnight production).
  6. Be of non-childbearing potential or using effective methods of birth control, as defined below:

Non-childbearing potential:

  1. Subject - not heterosexually active or practices sexual abstinence; or
  2. Female Subject/sexual partner - bilateral oophorectomy, bilateral tubal ligation and/or hysterectomy or has been postmenopausal with a history of no menses for at least 12 consecutive months; or
  3. Male Subject/sexual partner - vasectomised or has had a bilateral orchidectomy minimally three months prior to screening.

Effective birth control methods:

A double contraceptive method should be used as follows:

  1. Double barrier method which can include any 2 of the following: a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together); or
  2. Barrier method (one of the above) combined with hormone-based contraceptives or an intra-uterine device for the female Subject/partner; and are willing to continue practicing birth control methods throughout treatment and for 6 months (both male and female Subjects) after the last dose of study medication or discontinuation from study medication in case of premature discontinuation.

(Note: Hormone-based contraception alone may not be reliable when taking IMP; therefore, hormone-based contraceptives alone cannot be used by female Subjects or female partners of male Subjects to prevent pregnancy).

Exclusion Criteria:

Medical Criteria

  1. Evidence of clinically significant (as judged by the Investigator), metabolic, gastrointestinal, cardiovascular, musculoskeletal, ophthalmological, pulmonary, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied) including malaria. A rapid test for malaria may be carried out if indicated.
  2. Karnofsky performance status score of < 60%.
  3. Poor general condition where any delay in treatment cannot be tolerated per discretion of the Investigator.
  4. Clinically significant evidence of extrathoracic TB (e.g. miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis), as judged by the Investigator.
  5. History of allergy or hypersensitivity to any of the study Investigational Medicinal Products or related substances.
  6. Known or suspected current alcohol and/or drug abuse (positive urine drug screen) or history thereof within the past 2 years that is, in the opinion of the Investigator, sufficient to compromise the safety and/or cooperation of the Subject.
  7. For HIV infected Subjects:

    1. having a CD4+ count <100 cells/µL;
    2. with an AIDS-defining opportunistic infection or malignancies (except pulmonary TB);
    3. currently treated with or will need to initiate antiretroviral therapy (ART) which is not compatible with the allowed ARTs and is not considered an appropriate candidate for switching to a regimen of ARVs which is allowed as follows:

      • Triple nucleoside reverse transcriptase inhibitor (NRTI) based regimen consisting of zidovudine, lamivudine, and abacavir;
      • Nevirapine based regimen consisting of nevirapine in combination with any NRTIs;
      • Lopinavir/ritonavir (Aluvia™) based regimen consisting of lopinavir/ritonavir (Aluvia™) in combination with any NRTIs;
      • Raltegravir in combination with nucleoside reverse transcriptase inhibitors (NRTIs);
    4. cannot ensure a 2 week interval between commencing IMP and the start of ART.
  8. Having participated in other clinical study/ies with investigational agent/s within 8 weeks prior to trial start.
  9. Significant cardiac arrhythmia requiring medication.
  10. Subjects with the following at screening (per measurements and reading done by Central ECG):

    1. Marked prolongation of QT/QTc interval, e.g. confirmed demonstration of QTcF (Fridericia correction) or QTcB (Bazett correction) interval >450 ms at screening;
    2. History of additional risk factors for Torsade de Pointes, e.g. heart failure, hypokalemia, family history of Long QT Syndrome;
    3. Use of concomitant medications that are known to prolong the QT/QTc interval (see exclusion criteria 19);
    4. Any clinically significant, in the opinion of the Investigator, ECG abnormality.
  11. Females who are pregnant, breast-feeding, or planning to conceive a child during the study or within 6 months of cessation of treatment. Males planning to conceive a child during the study or within 6 months of cessation of treatment.
  12. Diabetes Mellitus resulting in hospitalization in the past year.
  13. Evidence of lens opacity on slit lamp ophthalmologic examination as defined by a grading of >1+ on the AREDS2 grading system.
  14. For males, any history of a clinically significant abnormality in the reproductive system.

    Specific Treatments

  15. Previously received treatment with PA-824, bedaquiline or moxifloxacin as part of a clinical trial.
  16. For the DS-TB treatment arms: treatment with any drug active against M. Tb within the 3 years prior to Day 1 (including but not limited to isoniazid, ethambutol, amikacin, bedaquiline, clofazimine, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides, metronidazole). Exceptions include the use of fluoroquinolones and metronidazole as short-term treatment (≤2 weeks) for Non-M.Tb infections. Treatment should have been discontinued at least 3 months prior to Day 1. Subjects who have previously received isoniazid prophylactically may be included in the trial as long as that treatment is/was discontinued at least 7 days prior to randomization into this trial.
  17. MDR-TB Subjects may have previously been treated for DS-TB with first-line TB drugs (isoniazid, rifampicin, ethambutol, pyrazinamide and/or streptomycin) and/or received ≤7 days MDR-TB treatment, provided that treatment is/was discontinued at least 7 days prior to randomization. It should be confirmed that the MDR-TB treatment can be safely stopped and the screening period is long enough to allow for a washout period of 5 times the longest half-life of the drugs.
  18. Any diseases or conditions in which the use of the standard TB drugs or any of their components is contra-indicated, including but not limited to acute gout, allergy to any TB drug, their component or to the IMP.
  19. Use of any drug within 30 days prior to dosing known to prolong QTc interval (including but not limited to amiodarone, bepridil, chloroquine, chlorpromazine, cisapride, cyclobenzaprine, clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, thioridazine). Exceptions may be made for Subjects that have received 3 days or less of one of these drugs or substances, if there has been a wash-out period before administration of IMP equivalent to at least 5 half-lives of that drug or substance. Subjects who have taken drugs with long elimination half-lives such as amiodarone should be discussed with the Sponsor.
  20. Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes (including but not limited to quinidine, tyramine, ketoconazole, fluconazole, testosterone, quinine, gestodene, metyrapone, phenelzine, doxorubicin, troleandomycin, cyclobenzaprine, erythromycin, cocaine, furafylline, cimetidine, dextromethorphan). Exceptions may be made for Subjects that have received 3 days or less of one of these drugs or substances, if there has been a wash-out period before administration of IMP equivalent to at least 5 half-lives of that drug or substance.
  21. Any ARVs other than allowable ARVs detailed in exclusion criteria no. 7 above.

    Based on Laboratory Abnormalities:

  22. Subjects with the following toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Disease (DMID) adult toxicity table:

    1. serum magnesium and calcium (corrected for albumin) levels outside of the laboratory's reference range
    2. lipase grade 3 or greater (>2.0 x ULN);
    3. creatinine grade 2 or greater (>1.5 x ULN);
    4. hemoglobin grade 4 (<6.5 g/dL);
    5. platelets > grade 2 (under 50x10(9) cells/L);
    6. serum potassium less than the lower limit of normal for the laboratory;
    7. aspartate aminotransferase (AST) grade 3 or greater (≥3.0 x ULN) to be excluded;
    8. alanine aminotransferase (ALT) grade 3 or greater (≥3.0 x ULN) to be excluded;
    9. alkaline phosphatase (ALP) grade 4 (>8.0 x ULN) to be excluded, grade 3 (≥3.0 - 8.0 x ULN) must be discussed with and approved by the Sponsor Medical Monitor;
    10. total bilirubin grade 3 or greater (≥2.0 x ULN, or ≥1.50 x ULN when accompanied by any increase in other liver function test) to be excluded, grade 2 (≥1.50 x ULN, or ≥1.25 x ULN when accompanied by any increase in other liver function test) must be discussed with and approved by the Sponsor Medical Monitor
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE South Africa,   Tanzania,   Uganda
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02193776
Other Study ID Numbers  ICMJE NC-005-(J-M-Pa-Z)
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Global Alliance for TB Drug Development
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Global Alliance for TB Drug Development
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Rodney Dawson University of Cape Town Lung Institute
PRS Account Global Alliance for TB Drug Development
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP